-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Stroke is an important cause of global morbidity and mortality
.
Platelet aggregation is involved in the pathogenesis of stroke; antiplatelet therapy interferes with the development of these events and plays an important preventive role
Compared with clopidogrel, the new generation of P2Y12 receptor inhibitors are more effective platelet inhibitors
.
Clopidogrel and prasugrel have the same active metabolites, but the latter has more effective biological activity, while ticagrelor, a direct-acting reversible P2Y12 receptor antagonist, inhibits ADP-mediated P2Y12-dependent platelets Gather
Some recent data indicate that ticagrelor has potential benefits for stroke prevention in high-risk groups
.
Recently, the THALES trial further validated the potential of ticagrelor and aspirin to prevent stroke
Based on the results of previous studies, there is growing interest in comparing ticagrelor alone and dual antiplatelet therapy to prevent ischemic stroke or transient ischemic attack (TIA)
.
In September 2021, András Komócsi from Hungary and others announced their research results on Stroke.
A total of 26 randomized clinical trials with 124495 patients were included in this NMA analysis
.
Compared with the control group, ticagrelor combined with aspirin significantly reduced the risk of ischemic stroke by 20% (RR, 0.
In the end, the author believes that ticagrelor combined with aspirin may provide a more favorable outcome for secondary stroke prevention in patients with vascular risk factors; however, this benefit may be accompanied by an increased risk of bleeding (including intracranial hemorrhage)
Original source:
Original source:Alexandra Bálint, Dániel Tornyos, et al.
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events in this message
